




PHARMACEUTICAL 2022

Alaunos Therapeutics Inc.
Rank 334 of 466





RealRate

PHARMACEUTICAL 2022

Alaunos Therapeutics Inc. Rank 334 of 466



The relative strengths and weaknesses of Alaunos Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Alaunos Therapeutics Inc. compared to the market average is the variable Property and Equipment, increasing the Economic Capital Ratio by 20% points. The greatest weakness of Alaunos Therapeutics Inc. is the variable Net Income, reducing the Economic Capital Ratio by 55% points.

The company's Economic Capital Ratio, given in the ranking table, is 32%, being 46% points below the market average of 78%.

Input Variable	Value in 1000 USD
Assets, Current	78,831
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	16,041
Liabilities, Non-Current	16,250
Other Assets	5,093
Other Compr. Net Income	0
Other Expenses	740
Other Liabilities	4,518
Other Net Income	-1,202
Other Revenues	398
Property and Equipment	10,941
Research and Development	49,643
Selling, General and Administrative Expense	27,564

Output Variable	Value in 1000 USD
Assets	94,865
Liabilities	36,809
Expenses	77,947
Revenues	398
Stockholders Equity	58,056
Net Income	-78,751
Comprehensive Net Income	-78,751
Economic Capital Ratio	32%